IMR Press / FBS / Volume 2 / Issue 2 / DOI: 10.2741/S87

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Molecular diagnosis of pancreatic cancer: where do we stand?
Show Less
1 Division of Laparoscopic and Bariatric Surgery, University of Maryland, Baltimore, MD, USA
2 Department of Surgery , General Surgery and Breast Unit, University of Catania, University Hospital, Catania, Italy
3 Department of Medical Oncology, National Cancer Institute, I.R.C.C.S. Aviano (PN)
4 Department of Surgery, Transplantation and Advanced Technologies; Vascular Surgery and Organ Transplant Unit, University of Catania, University Hospital, Catania, Italy
5 Fellowship in Surgical Physiopathology , Department of Surgery, University of Catania, University Hospital, Catania, Italy
6 Department of Internal Medicine and Medical Specialties, Section of Infectious Diseases, University of Catania, Garibaldi, Nesima Hospital, Catania, Italy

Academic Editor: Giovanni Li Volti

Front. Biosci. (Schol Ed) 2010, 2(2), 578–590; https://doi.org/10.2741/S87
Published: 1 January 2010
(This article belongs to the Special Issue Biochemical markers in biological fluids)
Abstract

Pancreatic cancer remains a disease with a dismal prognosis due mostly to its late diagnosis. An early diagnosis would have a significant impact on the prognosis and, eventually, on the incidence of the disease itself. Many progresses have been made in the molecular diagnosis of pancreatic cancer. High risk patients would likely benefits from biologic screening, before the general population. Most of the markers remain limited to phase I and II studies. The challenges include the lack of specificity of some of the markers, as well as the lack of standardization within the laboratories. Further research is necessary prior to the application of the currently known biomarkers for the diagnosis of pancreatic cancer.

Share
Back to top